Quantcast
Last updated on April 17, 2014 at 13:16 EDT

Latest Sirna Therapeutics Stories

2013-06-19 08:28:59

Invivofectamine® Rx-formulated therapeutic is 100-fold more potent than previous in-vivo transfection products from Life CARLSBAD, Calif., June 19, 2013 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announces a licensing agreement granting Suzhou Ribo Life Sciences (Ribo) the exclusive rights to develop and manufacture siRNA therapeutics in China using Life's Invivofectamine® Rx delivery technology. Ribo will formulate proprietary siRNA molecules...

2012-12-19 12:24:43

GAITHERSBURG, Md., Dec. 19, 2012 /PRNewswire/ -- Sirnaomics, Inc. (www.sirnaomics.com) announced today that the company has made a major breakthrough in its novel small interfering RNA (siRNA) therapeutic product against human papillomavirus (HPV) infection and cervical cancer which was presented by Dr. Alan Lu, Executive Vice President of Sirnaomics, in the 28(th) International Papillomavirus Conference held in San Juan, Puerto Rico from Nov 30(th) to Dec 6(th), 2012. Dr. Lu's presentation...

2012-11-05 04:21:49

LONDON, November 5, 2012 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN), a leading RNA interference (RNAi) therapeutics company, today announced that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance indicating that it will grant patents based on two applications: 12/986,389 and 13/230,084. These cover respectively interfering RNA molecules and lipid complexes used in drug delivery. The claims allowed on interfering RNA molecules cover any...

2012-06-25 02:26:44

GAITHERSBURG, Md., June 25, 2012 /PRNewswire/ -- Sirnaomics, Inc. (www.sirnaomics.com) announced today that the company has been awarded another NIH SBIR (Small Business Innovation Research) grant for developing its small interfering RNA (siRNA) therapeutic product STP705 to improve skin wound healing with minimized scar formation. This funding will further enhance the company's effort for perfection of its nanoparticle-based siRNA delivery systems and speed up the IND enabling studies for...

2012-06-06 02:25:13

LONDON, June 6, 2012 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading global RNA interference [http://silence-therapeutics.com/platform-technologies/rna-interference ] (RNAi) therapeutics company, on Monday presented the latest data from its ongoing Phase I study of Atu027, its lead internal therapeutics candidate, alongside the 2012 American Society of Clinical Oncology ("ASCO") Annual Meeting in Chicago, Illinois. At this...

2012-05-16 22:20:49

LONDON, May 17, 2012 /PRNewswire/ -- - Atu027, a First in Class RNAi Therapy, Demonstrates Potential - Antitumour Activity in Cancer Patients and Possible Biomarker Identified Silence Therapeutics to Announce New Data from Phase I Study of Atu027 in Solid Tumours At 2012 ASCO Annual Meeting Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading global RNA interference (RNAi) therapeutics...

2012-03-20 22:20:45

LONDON, March 21, 2012 /PRNewswire/ -- Silence Therapeutics plc [http://silence-therapeutics.com ] (AIM: SLN) ("Silence" or "the Company"), a leading RNA [http://silence-therapeutics.com/content/therapeuticplatform/overview.htm ] interference (RNAi [http://silence-therapeutics.com ]) therapeutics company, today announced the creation of a Scientific Advisory Board (SAB) with the appointment of two Key Opinion Leaders (KOLs) in the area of liver disease, Professor Dr. Dr. Detlef...

2012-03-09 09:20:00

LONDON, March 9, 2012 /PRNewswire/ -- Silence Therapeutics plc [http://silence-therapeutics.com ] (AIM: SLN) ("Silence" or "the Company"), a leading RNA [http://silence-therapeutics.com/content/therapeuticplatform/overview.htm ] interference (RNAi) therapeutics company, responds to comments that the Tuschl I (EP 1309726) patent has been upheld in European Opposition Proceedings without any modification. Concluding on 1 March 2012, the European Patent Office held oral opposition...

2012-02-10 01:00:00

LONDON, February 10, 2012 /PRNewswire/ -- -- Tony Sedgwick steps up to Chief Executive Officer from Chief Business Officer -- -- Thomas Christely resigns as a Director of the Company -- Silence Therapeutics plc [http://silence-therapeutics.com ] (AIM: SLN) ("Silence" or "the Company"), a leading RNA [http://silence-therapeutics.com/content/therapeuticplatform/overview.htm ] interference (RNAi)...

2012-01-09 01:00:00

LONDON, January 9, 2012 /PRNewswire/ -- - Third collaboration to investigate the potential application of Silence's proprietary RNAi delivery technologies in the development of novel microRNA-based therapeutics Silence Therapeutics plc [http://silence-therapeutics.com ] (AIM: SLN) ("Silence"), a leading RNA [http://silence-therapeutics.com/content/therapeuticplatform/overview.htm ] interference (RNAi) therapeutics company, announces that it has signed an agreement with...